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Background: Metabolic syndrome (MS) is a cluster of metabolic abnormalities, which has been regarded as a
pivotal risk factor for cardiovascular diseases. Recent studies focusing on the relationship between MS and cancer
have recognized the significant role of MS on carcinogenesis. Likewise, growing evidence suggests that MS has a
strong association with increased renal cell carcinoma (RCC) risk. This review outlines the link between MS and RCC,
and some underlying mechanisms responsible for MS-associated RCC.
Materials and methods: A National Center for Biotechnology Information PubMed search (www.pubmed.gov) was
conducted using medical subject headings ‘metabolic syndrome’, ‘obesity’, ‘hypertension’, ‘diabetes’, ‘dyslipidemia’,
and ‘renal cell carcinoma’.
Results: This revealed that a variety of molecular mechanisms secondary to MS are involved in RCC formation,
progression, and metastasis. A deeper understanding of these molecular mechanisms may provide some strategies
for the prevention and treatment of RCC.
Conclusions: In summary, there is a large body of evidence regarding the link between MS and RCC, within which
each component of MS is considered to have a close causal association with RCC.
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Background
Metabolic syndrome (MS) has become an almost ubiqui-
tous severe health issue across the globe. It is estimated
that more than 40% U.S. residents over the age of
60 years have MS [1], with a prevalence of approxi-
mately 25% in European and Latin populations [2,3].
Over recent decades there has been an alteration of diet-
ary pattern and lifestyle in Chinese people, and subse-
quently an elevated morbidity associated with MS year
by year. According to an analysis of data in 2005, up to
20% Chinese adults suffered from MS [4]. The concern
regarding MS was primarily focused on its contribution
to increased cardiovascular disease and type 2 diabetes
mellitus risk. Recently, the relationship between MS and
cancer has been highlighted by the observation that MS
is associated with high morbidity and mortality for cer-
tain types of cancer. This review summarizes evidence in
support of the relationship between MS and renal cell* Correspondence: dwyeli@163.com
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and therapeutic interventions.
Definition of metabolic syndrome
MS was first described using the term ‘syndrome X’ by
Reaven in 1988 [5], with insulin resistance (IR) as the
common and elementary denominator. It comprises a
cluster of metabolic abnormalities, each of which is an
important atherosclerotic risk factor. With a deeper un-
derstanding of MS, more sophisticated mechanisms have
been revealed, and IR is recognized as one of the most
significant factors. Because IR is not easily measured clin-
ically, it is not included in all of the definitions developed
by different organizations, whereas abdominal obesity,
dyslipidemia, hypertension, and impaired glucose regula-
tion have been adopted in almost all of the diagnostic cri-
teria. For example, NCEP/ATP III (National Cholesterol
Education Program/Adult Treatment Panel III) sets three
of five of the following criteria as necessary for a diag-
nosis of MS: fasting glucose ≥110 mg/dl; hypertriglyc-
eridemia ≥150 mg/dl; low high-density-lipoprotein (HDL)
levels - male <40 mg/dl, female <50 mg/dl; abdominal
obesity - male >102 cm, female >88 cm waist circum-
ference; hypertension, ≥130/≥85 mmHg. In 1998, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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unifying definition and revised this in the following
year: impaired glucose regulation and/or hyperinsuli-
nemia (fasting glucose ≥110 mg/dl; post-prandial glu-
cose >140 mg/dl; fasting serum insulin: third quartile
for control group) and two or more criteria are necessary:
(1) hypertension, ≥140/≥90 mmHg; (2) hypertriglyc-
eridemia, ≥150 mg/dl; low HDL levels - male <35 mg/dl,
female <39 mg/dl; (3) abdominal obesity - waist:hip
ratio, male >0.90, female >0.85, and/or body mass index
(BMI) ≥30 kg/m2; (4) microalbuminuria, ≥20 μg/min.
MS and cancer
There is increasing evidence to indicate that MS might
play an important role in the etiology and progression of
certain types of cancers. The association of MS with
liver, pancreatic, gastric, colorectal, bladder, prostate,
endometrial, cervical, and postmenopausal breast can-
cers have all been reported [6-14]. A systematic review
published in 2012 showed that MS was associated with
pancreatic and rectal cancer, and these associations were
stronger in women than in men. Additionally, associa-
tions were different for ethnic groups: stronger associa-
tions were observed in Asian populations for liver
cancer, in European female populations for colorectal
cancer and in U.S. Caucasian populations for prostate
cancer [15]. Cancer patients with concomitant MS seem
to have a worse prognosis. Buschemeyer et al. reported
that obese patients with prostate cancer were more likely
to suffer from high-grade and aggressive cancer [16].
Compared with those with high cholesterol levels, men
with normal or borderline levels were less likely to de-
velop high-grade prostate cancer, particularly when con-
sidering cases in which the cancer was confined to the
pancreas [17]. A conclusion that MS is a risk factor for
lethal prostate cancer has also been reported [11]. Fur-
ther, the rates of liver metastasis and tumor recurrence
were higher in patients with colorectal cancer accom-
panied by MS [18], and Pasanisi et al. observed a higher
recurrence rate in breast cancer patients with concomi-
tant MS [19].
MS and renal cell carcinoma
Renal cell carcinoma (RCC), a common type of urologic
tumor, accounts for 2% to 3% of all malignancies. Ac-
cording to data provided by the WHO, the morbid-
ities of RCC appear to be showing an upward trend in
recent years in a range of regions and ethnicities, ex-
cept for in Scandinavia [20]. Although the etiology of
RCC remains unclear, previous research has identified
smoking and diet as risk factors. Moreover, data from
a large set of studies suggest a significant association
between RCC and the major components of MS, among
which obesity and hypertension have been listed asconfirmed etiological factors in the guidelines by many
organizations, for example, the European Association of
Urology, the American Urological Association, and the
Chinese Urological Association.
Obesity and RCC
Accumulating evidence indicates that, as an independent
risk factor, obesity is significantly associated with RCC
[21]. A study whose conclusion was published in the
British Journal of Cancer analyzed 22 independent clin-
ical studies available in MEDLINE from 1966 to 1998.
By means of quantitative summary analysis, the authors
reported that the link between MS and RCC was stron-
ger among men with higher BMI, and the relative risk
for men and women together was 1.07 (95% CI: 1.05-
1.09) per unit of increase in BMI (one unit of increase in
BMI corresponds to 3.1 kg for a man of an average
height of 1.77 m, and to 2.7 kg for a woman of an aver-
age height of 1.64 m) [22]. Leiba and his colleagues con-
ducted a study comprising 19,576,635 person-years of
follow-up and drew a conclusion that being overweight
in late adolescence was a substantial risk factor for RCC,
and European origin was independently associated with
excess risk compared with Asian or African origin [23].
Nevertheless, it is of interest that obesity seems to be a
favorable factor in terms of prognosis of RCC, despite its
contribution to increased RCC risk. For patients with
organ-confined but not advanced RCC, being overweight
improved their cancer specific survival [24]. Another
study also reported that cancer-specific survival time,
but not overall survival time, was notably prolonged for
patients with increasing BMI (>30 kg/m2) who had re-
ceived radical nephrectomy [25].
Some recently published studies showed that com-
pared with subcutaneous adipose tissue, visceral adipose
tissue seemed more harmful to health, and to be a better
indicator than BMI of obesity. In addition to the trad-
itional measure of waist:hip ratio, visceral fat area (VFA)
measured using imaging methods has become a new re-
search ‘hotspot’. Zhu et al. investigated the relationship
between tumor grade and VFA in patients with RCC of
stage T1a and found that the percentage of visceral adi-
pose tissue was significantly associated with higher Fuhr-
man grade and might be an independent predictor of
high grade RCC [26]. However, visceral adipose tissue is
likely to play a protective role in advanced RCC patients
who are receiving first-line targeted therapy, such as so-
rafenib and sunitinib. The fact that those patients with
higher levels of VFA had a longer progression-free sur-
vival time and OS has been reported in a retrospective
study [27]. The reason why obesity is associated with in-
creased RCC risk but improved prognosis is not yet well
understood. It has been speculated that the development
of cachexia might be suppressed by obesity. Further
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mechanism.
Hypertension and RCC
The conclusion that hypertension can increase the risk
of RCC has been confirmed by a large set of clinical
studies. A study group evaluated the relationship be-
tween hypertension and RCC by examining the health
records of 363,992 Swedish men, with subsequent follow-
up studies. After the first 5 years of follow-up had been
excluded to reduce possible effects of preclinical disease,
the researchers still found a direct association between
higher blood pressure and a higher risk of RCC [21]. Colt
et al. also performed a clinical study in the U.S. and
found hypertension doubled RCC risk, with OR of 1.9
(CI: 1.5-2.4) for Caucasians, and 2.8 (CI: 2.1-3.8) for
African-Americans [28]. A similar conclusion was also
reported in a Chinese population-based study [29]. Subtle
changes of renal function prior to clinical hypertension
may make the kidney more susceptible to carcinogenesis,
and some angiogenic and other growth factors that are
involved in hypertension may also participate in renal
carcinogenesis and progression.
It is noteworthy that some interventions aiming to re-
duce hypertension may also increase the risk of RCC, of
which diuretics merit further investigation. As the first
line antihypertensive drugs that can reduce morbidity
and mortality of cardiovascular disorders, diuretics are
widely administrated owing to their satisfactory effect
and relatively low expense. However, emerging evidence
suggests that the long-term use of diuretics may be asso-
ciated with RCC [30], being especially significant for
women [31]. Nevertheless, because this conclusion is still
controversial and the reason for it remains unclear, large-
scale studies to corroborate the conclusion and clarify the
mechanisms are warranted.
Diabetes and RCC
The relationship between diabetes and cancer is quite
close, because it is presently considered that there may
exist ‘common soil’ responsible for both diabetes and
cancer. In other words, some risk factors for diabetes
likewise render people more susceptible to cancer. There
are also numerous epidemiological studies focusing on
the link between diabetes and RCC, showing an elevated
cancer morbidity and mortality in diabetes patients.
Lindblad and colleagues conducted a large scale follow-
up study (1 to 25 years) in a total of 153,852 patients
with a diagnosis of diabetes in Northern Europe. After
exclusion of the first year of observation, they found that
standardized incidence ratios (SIRs) were 1.7 (95% CI:
1.4-2.0) in women and 1.3 (95% CI: 1.1-1.6) in men, and
standardized mortality ratios (SMRs) were 1.9 (95% CI:
1.7-2.2) in women and 1.7 (95% CI: 1.4-1.9) in men.Thus, both morbidity and mortality of RCC increased in
patients with diabetes in comparison with the general
population [32]. Another study with a follow-up of
32 years performed in the U.S. reported type 2 diabetes
was independently associated with an increased risk of
RCC in women [33].
Another current research ‘hotspot’ concerning the im-
pact of anti-diabetic drugs on tumor development pro-
vides indirect evidence about the role of diabetes on the
etiology of cancers. Insulin can promote mitosis and cell
proliferation, which results in the concern about its car-
cinogenic effect. However, no compelling evidence that
exogenous insulin or insulin analogues may elevate can-
cer risks has so far been presented. Many studies have
revealed the inhibitory effect of metformin on many
kinds of tumor cells, including RCC cells. Metformin,
one of the commonly used oral anti-diabetic drugs, is
able to inhibit the growth of RCC cells in vivo and
in vitro, through induction of apoptosis and G0/G1 cell
cycle arrest [34,35]. No consensus as to the effect of sul-
fonylureas on cancer has been reached so far. Deeper
and more systematic work needs to be done to clarify
the relationship between anti-diabetic drugs and tumor.
Dyslipidemia and RCC
Lipid profiles include cholesterol (CH), triglyceride (TG),
and some lipoid constituents, such as phospholipids, of
which CH and TG are clinically important. Only in the
form of lipoprotein, for example, low-density-lipoprotein
(LDL) and HDL, can CH and TG be transported to the tis-
sues and be metabolically active. There are many studies
validating the contribution of dyslipidemia to carcinogen-
esis of various cancers. An elevated risk of esophageal can-
cer and colon cancer was observed in people with high
levels of TG [36,37], and hypercholesterolemia has been
suggested as a risk factor for rectal cancer [36]. High serum
CH and TG levels raised the risk of prostate cancer and
low HDL levels were associated with breast cancer, lung
cancer, and non-Hodgkin’s lymphoma [38-41].
Clear cell RCC, the most common type of renal malig-
nancy, is characterized histologically by sterol storage in
tumor cells, which prompts some abnormality in lipid
metabolism which plays an important role in the forma-
tion and progression of RCC. However, little research
has been conducted which directly focuses on the asso-
ciation between RCC and lipid disorders. In a prospective
cohort study, Van Hemelrijck et al. reported that TG was
the only lipid component for which a statistically signifi-
cant association was observed with RCC [42], whereas
another prospective study reported a decreased risk of
RCC associated with higher serum CH levels, albeit with
marginal statistical significance [43]. Statins (inhibitors of
3-hydroxy-3-methylglutaryl coenzyme A reductase) that
are used for the treatment of lipid disorders, especially
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velopment of RCC. Horiguchi et al. reported that fluvas-
tatin had a notable inhibitory effect in vitro on tumor
growth, invasion, angiogenesis, and metastasis of RCC
cells [44], which provided indirect evidence of the rela-
tionship between dyslipidemia and RCC. However, given
the relative paucity of laboratory and clinical research
compared with that relating to obesity, hypertension, and
diabetes, further studies regarding the effect of dyslipid-
emia on RCC development are warranted.
Mechanisms
The mechanisms that underlie the role of MS on RCC
carcinogenesis are complicated, involving insulin resistance
(IR), inflammation, angiogenesis, cell-stroma interaction,
and many other important aspects. A sophisticated net-
work including various factors and signaling pathways is
composed of these interrelated components, regulating the
cross-talk between MS and RCC.
Insulin resistance
Hyperinsulinemia and IR are considered the primary
basis of the metabolic impairment associated with MS.
Insulin is one of the most important anabolic hormones
that is able to stimulate cell proliferation. Harmful local
and systemic reactions, including intracellular lipid accu-
mulation in adipocytes, mitochondrial and endoplasmic
reticulum stress, and IR, can be induced by obesity, ac-
companied by changes of circulating factors such as adi-
pokines, free fatty acids and a variety of inflammatory
mediators.
The insulin-like growth factor (IGF) family and the
changes of its components resulting from IR play a cru-
cial role in tumor formation and progression. The IGF
family consists of IGF-1, IGF-2 and their receptors,
IGF-1R and IGF-2R, as well as six types of IGF binding
proteins (IGFBPs), IGFBP-1 to 6. IGF-1 and IGFBP-3
are important members of the IGF family, and have
been investigated in many studies to understand their
role in RCC carcinogenesis. Rasmuson et al. evaluated the
prognostic information of serum IGF-1 in 256 patients
with RCC, and reported that IGF-1 did not correlate with
tumor stage or grade, whereas tumor stage and IGF-1
levels were independent prognostic factors using a multi-
variable analysis. They concluded that high serum IGF-1
levels at diagnosis were related to favorable prognosis in
RCC [45]. In the human RCC cell lines Caki-2 (from a pri-
mary tumor) and SK-RC-52 (from a metastasis), IGF-1
may enhance transforming growth factor-β (TGF-β) sig-
naling and raise IGFBP-3 levels with TGF-β acting in syn-
ergy [46]. Through activation of mitogen-activated protein
kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)
signaling pathways, IGF-1 that is bound to IGF-1R may
play a role in promotion of mitosis and cell migration,and inhibition of apoptosis [47]. Additionally, IGF-1 can
stimulate tumor angiogenesis by increasing vascular
endothelial growth factor (VEGF) levels [48]. IGFBP-3
may inhibit the activity of IGF-1 through competitive
binding to IGF-1, because IGF-1 has a higher affinity for
IGFBP-3 than for its receptors. Moreover, IGFBP-3 regu-
lates the biological functions of IGFs, by means of con-
trolling their transport from circulation into tissues,
modulating their metabolism and clearance, and estab-
lishing their specific location on tissues and cells [49]. Al-
though no correlation was observed between serum
IGFBP-3 levels and RCC [45,50], high expression of
IGFBP-3 was found in clear cell RCC tissue, and high grade
(Fuhrman grades 3 and 4) clear cell RCC showed higher
IGFBP-3 staining intensity than low grade clear cell RCC
[51]. Considering the close link between IGFs and RCC,
potential therapeutics targeting IGFs might be promising
for the treatment of RCC.
Inflammation
As a typical alteration in obesity, both hyperplasia and
hypertrophy of adipocytes may lead to tissue hypoxia,
and subsequently the induction of a series of pro-
inflammatory cytokines. These cytokines, such as tumor
necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8, IL-10,
and macrophage inflammatory protein 1 (MIP-1), have
been shown to stimulate angiogenesis and promote IR, as
well as being pivotal to tumor development.
Under the conditions of MS, elevated levels of reactive
oxygen species (ROS) (together with pro-inflammatory
cytokines and certain mediators involved in inflammation
status, such as NF-κB and cyclooxygenase-2 (COX-2)) are
known to affect cell apoptosis, proliferation, and invasion.
It has been shown that both IL-6 and IL-10 are strongly
expressed in RCC cells and stroma. Further, IL-10 levels
were higher in more advanced (pT3) tumors, suggesting
that IL-6 and IL-10 may be useful markers associated with
the development and progression of RCC [52]. TNF-α, an-
other vital cytokine, was found to be positively correlated
with IR and waist circumference [53]. Likewise, TNF-α is
capable of promoting proliferation and metastasis of RCC
cells, and mediating epithelial-mesenchymal transition of
RCC via GSK3β [54]. ROS directly affect RCC and induce
cell apoptosis via activation of the NF-κB pathway and
downregulation of COX-2 [55].
Considerable interest has been devoted to COX-2, a
key enzyme in prostaglandins synthesis, and its contri-
bution to cancer. It has been documented that COX-2 is
overexpressed in various cancers, including RCC, in
which it was correlated with VEGF expression [56,57].
Additionally, IGF-IR and COX-2 may produce a syner-
gistic effect in the oncogenesis and progression of RCC
[58]. Nevertheless, Kankuri et al. reported that COX-2
expression was associated with slow development of
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[59]. As the current first-line drug targeting VEGF path-
ways, sunitinib has been applied in the clinic for the
treatment of advanced RCC. It has been reported that
Cox-2 inhibition enhanced the activity of sunitinib in
human RCC xenografts [60].
Adipokines
Adiponectin, which is primarily secreted by white adi-
pose tissue, functions as a regulator of glucose and lipid
metabolism and energy homeostasis. In addition to over-
all obesity, central fat distribution is thought to be an in-
dependent negative predictor of serum adiponectin [61],
and weight loss may increase serum adiponectin levels
[62]. Adipose tissue hypoxia may also result in the re-
duction of adiponectin and further research has shown
that hypoxia and TNF-α downregulate the activity of the
adiponectin gene promoter [63]. The anti-tumor role
of adiponectin has been ascribed in part to its anti-
inflammatory and anti-proliferative effect, as well as
antagonism to IR. It was found that serum adiponectin
levels were adversely associated with RCC [64]. Moreover,
Pinthus et al. reported that low blood adiponectin levels
had a strong correlation with tumor size and metastasis of
RCC, and could potentially be used as a biomarker [65]. In
vitro experiments have demonstrated that adiponectin can
inhibit tumor growth via activating AMP-activated protein
kinase (AMPK), thereby downregulating mammalian tar-
get of rapamycin (mTOR) pathways [66]. Additionally, as
an endogenous inhibitor, adiponectin plays an inhibitory
role on tumor angiogenesis [67].
Another important adipocyte-specific protein pro-
duced predominantly by white adipose tissue is leptin,
which acts centrally to mediate satiety and bodyweight
[68]. Uncontrolled energy intake and being overweight
take place as a result of abnormal levels and/or function
of leptin. Elevated levels of serum leptin and overex-
pression of leptin receptors are associated with RCC
invasion and progression, and activation of the extracel-
lular signal-regulated kinases (ERK1/2) and janus kinase/
signal transducer and activator of transcription 3 (JAK/
STAT3) signaling pathways participates in leptin-mediated
proliferation of RCC Caki-2 cells [69-71]. By suppressing
apoptosis, promoting cell proliferation and upregulat-
ing VEGF via hypoxia-inducible factor-1α (HIF-1α) and
NF-κB, leptin boosts carcinogenesis [72]; HIF-1α and
VEGF are thus involved as crucial factors promoting RCC
formation and development.
Peroxisome proliferator- activated receptors (PPARs)
PPARs belong to the nuclear hormone receptor super-
family and consist of three subtypes: PPARα, PPARβ,
and PPARγ. These ligand-activated transcription factors
contribute significantly to MS and other diseases. Forexample, PPARα can activate fatty acid catabolism and
PPARβ participates in fatty acid oxidation. With respect
to PPARγ, it has been shown to improve IR, regulate adi-
pocyte differentiation, and play an important role in in-
flammation, autoimmune diseases, and cancers. Many
experiments delineated a high expression of PPARγ in
RCC tissue. PPARγ ligands were found to inhibit human
RCC cell proliferation by induction of apoptosis and G0/
G1cell cycle arrest [73,74]. Pioglitazone is a highly select-
ive type of PPARγ ligand that serves as an insulin
sensitizer and is used to treat patients with type 2 dia-
betes. The multiple antitumor effects of pioglitazone on
RCC in vitro, such as suppression of cell growth, induction
of apoptosis and inhibition of VEGF and basic fibroblast
growth factor secretion, were reported by Yuan et al. [75].
A recent piece of research indicated that 15-deoxy-
Delta12,14-prostaglandin J2 (a novel kind of PPARγ
ligand) exerts cytotoxic effects on RCC cells via activa-
tion of c-Jun N terminal kinase (JNK)/MAPK and Akt
pathways, in addition to induction of apoptosis [76]. Fur-
thermore, therapies targeting PPARα are applied for dys-
lipidemia, and PPARβ agonists may be useful to treat
obesity, diabetes, and cardiovascular diseases. All of the
above research demonstrates that PPARs are potent thera-
peutic targets for MS and cancer.
Hypoxia-inducible factors (HIFs)
More and more evidence has reported the contribution
made by HIFs to MS. Hyperplasia and hypertrophy of adi-
pocytes may lead to local hypoxia, which subsequently
upregulates HIF expression and augments macrophage in-
filtration [77]. In cultured adipocytes and preadipocytes,
overexpression of HIF-1α was also detected when the cells
were exposed to hypoxia [78]. Hyperglycemia interferes
with HIF-1α stabilization, although the mechanisms are
not well-defined. Conversely, unbalanced HIF-1α signaling
impairs β-cells, causing insufficient insulin secretion and
IR [79-82]. A study investigating the effect of HIF-1α on
obesity and diabetes found the HIF-1α knockout mice
manifested resistance to weight gain, while ameliorating
IR [83]. Venous hypertension stimulates HIF-1 overex-
pression, and consequent upregulation of VEGF [84]. In
an oxygen-deficient environment, activation of the HIF
signaling pathway results in lipid accumulation, and
downregulates PPARα expression in a HIF-1-dependent
manner [85]. It has been documented that exposure to
hypoxia increases IL-6, leptin and monocyte migration in-
hibitory factor expression of adipocytes in vitro, however it
was also shown to decrease adiponectin expression [78].
The role of hypoxia in RCC carcinogenesis has been
verified. As a response to oxygen deficiency, HIFs not
only participate in energy homeostasis, such as glucose
and lipid metabolism, but also have effects on tumor de-
velopment, by means of regulating the cell cycle, apoptosis,
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tumor microvessel density in xenografts, as well as being
overexpressed in RCC [86]. Additionally, high expression
of HIF-1α seems to indicate a poor prognosis [87]. In a
retrospective study examining the prognostic prediction of
HIF-1α in metastatic RCC patients, researchers found that
patients with high HIF-1α expression had significantly
worse survival than those with low expression (median
survival: 13.5 versus 24.4 months, respectively) [88].
High expression of HIFs in RCC is closely related to
inactivation of the von-Hippel-Lindau (VHL) gene. Som-
atic mutations in this gene are detected in approximately
50% of sporadic RCC, while VHL hypermethylation is
seen in 10% to 20% of sporadic RCC [89]. As the VHL
gene product, pVHL is absent owing to the inactivation
of VHL, which mimics hypoxia and elicits a constitutive
up-regulation of HIF-1α, via NF-κB activation [90]. As a
result of HIF-1α overexpression, several factors involved
in carcinogenesis and angiogenesis, such as VEGF,
platelet-derived growth factor-β (PDGF-β) and TGF-β,
are upregulated. Although more comprehensive research
is needed, it is believed that hypoxia acts as a common
key factor in both MS and RCC; the significance of fur-
ther research lies in revealing the mechanisms and devel-
oping therapeutic interventions.
Mammalian target of rapamycin (mTOR)
mTOR, a high molecular weight serine-threonine kinase
which belongs to the superfamily of phosphatidylinositol
3-kinase (PI3K)-related kinases, is involved in cell growth,
proliferation, autophagy, survival, metabolism, and angio-
genesis. Deregulation of the PI3K signaling pathway is a
feature of various tumors, and it is estimated to account
for up to 30% of all human cancers [91,92]. MS is able
to trigger changes in signals upstream of mTOR, and
then regulate the processes of downstream pathways
via mTOR, including protein synthesis, lipid metabol-
ism, and mitochondrial metabolism. Insulin and IGF-1
may promote cell anabolism through mTOR. If glucose
regulation is impaired, abnormality of some growth fac-
tors pathways, for example, IGF-1, will result in im-
proper activation of mTOR and/or inactivation of mTOR
inhibitors, causing various pathologies, including cancer.
Meanwhile, an imbalance in the mTOR pathway leads to
deterioration of IR [93], resulting in a vicious cycle. In
the course of inflammation, TNF-α activates IκB kinase-β
(IKKβ), which then inactivates mTOR inhibitors, thereby
activating the mTOR pathway [94]. Further, obesity can
raise mTOR levels, which is also involved in HIF-1α
translation [95]. Conversely, hypoxia activates mTOR in-
hibitors via AMPK, leading to blockage of the mTOR
pathway [96].
Mutation of the tumor suppressor PTEN and activa-
tion of PI3K, both of which are common in many kindsof cancers, mediate hyperactivation of mTOR. In some
studies, researchers have detected low PTEN expression,
and high expression of PI3K/mTOR, in clear cell RCC
[97,98]. Further, high PI3K/mTOR expression seems to
be associated with poorer prognosis [99,100]. Given the
importance of mTOR for RCC, great progress has been
made in targeting mTOR. Everolimus and Temsirolimus
have both been approved by the FDA to treat advanced
RCC.
Conclusions
There is abundant evidence regarding the link between
MS and RCC, and each component of MS may have a
close causal association with RCC. Recent studies have
generated exciting findings on the molecular basis of
MS-associated RCC. Understanding the molecules in-
volved may provide clues to prevent carcinogenensis
in people with MS. Therapeutic interventions target-
ing these molecular mechanisms likewise manifest a
positive perspective for the treatment of RCC. Further,
because MS derives at least in part from an unhealthy
lifestyle, maintaining a healthy lifestyle may be important
in the prophylaxis of many cancers, including RCC.
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